EUCTR2022-004149-11-Outside-EU/EEA进行中（未招募）1 期
Phase 4, Multicenter, Prospective, Interventional, Post-Marketing Study in Hemophilia A Patients in India Receiving ADVATE as On-Demand or Prophylaxis Under Standard Clinical Practice - ADVATE INDIA PMC Study
Takeda Biopharmaceuticals India Pvt. Ltd.0 个研究点目标入组 50 人开始时间: 2023年7月27日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. The participant or legally authorised representative (in case of study participants <18 years of age) gave written informed consent to participate in the study.
- •2. Participant of any age with hemophilia A.
- •3. Participant defined as a previously treated patient (PTP):
- •a. Participant aged >=6 years that has been previously treated with plasma-derived and/or recombinant FVIII concentrate(s) for a minimum of 150 exposure doses (EDs).
- •b. Participant aged less than <6 years that has been previously treated with plasma-derived or recombinant FVIII concentrate(s) for a minimum of 50 EDs.
- •4. Participant as negative history of FVIII inhibitors and negative inhibitor at screening defined as less than 0.6 Bethesda units (BU) per millilitre (Nijmegen-modified Bethesda assay).
- •5. Participant is human immunodeficiency virus negative (HIV-); or human immunodeficiency virus positive (HIV+) with stable disease and cluster of differentiation 4 (CD4+) count >=200 cells per cubic millimetre (mm^3), as confirmed by central laboratory at screening.
- •6. Participant is hepatitis C virus negative (HCV-) by antibody or polymerase chain reaction (PCR) testing (if positive, anti-body titre will be confirmed by PCR), as confirmed by central laboratory at screening; or hepatitis C virus positive (HCV+) with chronic stable hepatitis.
- •7. Participant is willing and able to comply with the requirements of the protocol.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 50
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 26
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Participant has known hypersensitivity to mouse or hamster proteins or to any of the excipients of FVIII (factor VIII) concentrates.
- •2. Participant has been diagnosed with bleeding disorder(s) other than congenital hemophilia A, such as acquired hemophilia A, von Willebrand´s disease (VWD) or thrombocytopenia (platelet count <100,000 per millilitre).
- •3. Participant has received treatment for hemophilia A with non-FVIII products or concentrates (example, emicizumab [Hemlibra®]) in the 6 months prior to screening.
- •4. Participant has severe chronic hepatic dysfunction (example, >=5 times upper limit of normal alanine aminotransferase [ALT], aspartate aminotransferase [AST] or international normalised ratio [INR] >1.5 as confirmed by central laboratory at screening).
- •5. Participant has planned or is likely to have, surgery during the study period.
- •6. Participant has a clinically significant medical, psychiatric, or cognitive illness, or recreational drug or alcohol use that, in the opinion of the investigator, would affect participant's safety or compliance.
- •7. Participant currently receiving or is scheduled to receive during the course of the study, an immunomodulating drug (example, corticosteroid agents at a dose equivalent to hydrocortisone >10 milligram per day, or a-interferon) other than antiretroviral chemotherapy.
- •8. Participant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrolment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
- •9. Participant is a family member or employee of the investigator.
研究者
相似试验
进行中（未招募）
4 期
Safety of ADVATE in previously treated Indian patients for treatment of mild , moderate and severe bleeding episodes in Haemophilia ACTRI/2021/10/037406Baxalta US Inc50
进行中（未招募）
1 期
A Post Marketing Surveillance (PMS) Study of RIXUBIS in IndiaHemophilia BEUCTR2022-002520-13-Outside-EU/EEABaxalta Innovations GmbH
进行中（未招募）
4 期
A Post-marketing study receiving RIXUBIS as on-demand or Prophylaxis under standard clinical practice in patients with Hemophilia BCTRI/2018/07/014754Baxalta Innovations GmbH
进行中（未招募）
1 期
Study the effect of Landiolol on elevated heart rate by septic shock patientsAdult patients in ICU with septic shock who remain tachycardic (HR =95 bpm) and require vasopressor therapy to maintain a Mean arterial pressure (MAP) of =65 mmHg after a hemodynamic optimization period (at least 12 hours and up to 36 hours).MedDRA version: 20.0Level: PTClassification code 10043071Term: TachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 23.1Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-002138-22-PLAOP Orphan Pharmaceuticals AG200
进行中（未招募）
1 期
Study the effect of Landiolol on elevated heart rate by septic shock patientsAdult patients in ICU with septic shock who remain tachycardic (HR =95 bpm) and require vasopressor therapy to maintain a Mean arterial pressure (MAP) of =65 mmHg after a hemodynamic optimization period (at least 12 hours and up to 36 hours).MedDRA version: 20.0Level: PTClassification code 10043071Term: TachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-002138-22-EEAOP Orphan Pharmaceuticals AG200